期刊文献+

肾癌遗传学研究进展 被引量:7

Advances in genetics of kidney cancer
下载PDF
导出
摘要 肾癌是一类具有多种组织类型及不同遗传背景的癌症。目前至少有10种类型的肾细胞癌。其中最常见的是透明肾细胞癌,其次是乳头状肾细胞癌、嫌色肾细胞癌和集合管细胞癌。而其它的较少见。由于肾癌具有高度的遗传异质性,现在已发现了很多染色体畸变和基因的突变都可导致肾癌。而且不同类型的肾癌,其致癌基因也不同。如VHL基因突变一般引起透明肾细胞癌,而FH基因则导致乳头状肾细胞癌。近年来,新技术的发展和应用,新的肾癌相关基因的数目也在增加。如最近的外显子组序列分析就找到了一批与透明肾细胞癌有关的基因,包括PBRM1、BAP1、SET2和JARID1c等重要的肾癌相关基因。有些透明肾细胞癌同时带有两个以上基因的突变。随着新技术的出现和研究的深入,越来越多的肾癌基因及各类肾癌标记将会被发现。 Kidney cancer is known to have different histological types with distinct genetic profiles. There are at least 10 subtypes of kidney cancer. The most common subtype is clear cell renal cell carcinoma (RCC) , followed by papillary RCC, chromophobe RCC, and collecting duct carcinoma, etc. Since its high genetic heterogeneity, kidney cancer can be caused by chromosomal abnormalities and mutations in many genes, and each subtype of RCC has its own affected genes. For instance, VHL is associated with clear cell RCC, while FH mutations cause papillary RCC. An increased number of genes were found to be involved in RCCs in the past years. Recent exome - sequencing has revealed a group of genes involved in clear cell RCC tumorigenesis such as PBRM1, BAP1, SETD2, and JARIDlc. Combinational mutations of these genes were also identified in a proportion of clear cell RCCs. With the advent of new genetic technologies, more and more RCC - related genes/markers will be identified.
作者 陈金东
出处 《遵义医学院学报》 2014年第2期132-137,共6页 Journal of Zunyi Medical University
关键词 肾癌 肾上皮细胞癌 肾癌遗传异质性 RCC基因 肾癌标记 kidney cancer renal cell carcinoma genetic heterogeneity RCC genes kidney cancer markers
  • 相关文献

参考文献42

  • 1Ferlay J, Shin H R, Bray F, et al. Estimates of world- wide burden of cancer in 2008 : GLOBOCAN 2008 [ J ]. International journal of cancer Journal international du cancer,2010,127 ( 12 ) :2893 - 2917.
  • 2Lopez - Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO classification of the renal tumors of the adults [ J ]. Eur Urol,2006,49(5 ) :798 - 805.
  • 3Murtaza B, Mahmood A, Akmal M, et al. Pattern of malig- nant renal tumours using 2004 WHO classification of renal tumours on radical nephrectomy[ J]. J Ayub Med Coil Ab- bottabad, 2011,23 (3) :74 - 78.
  • 4Ross H, Martignoni G, Argani P. Renal cell carcinoma with clear cell and papillary features [ J ]. Arch Pathol Lab Med,2012,136(4) :391 -399.
  • 5Chen J, LuiW O, Vos M D,et al. The t(1;3) break- point- spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas[ J]. Cancer Cell ,2003, 4(5) :405 -413.
  • 6Yusenko M V, Nagy A, Kovacs G. Molecular analysis of germline t( 3 ;6) and t( 3 ; 12) associated with convention- al renal cell carcinomas indicates their rate - limiting role and supports the three - hit model of carcinogenesis [ J ]. Cancer genetics and cytogenetics ,2010,201 ( 1 ) : 15 - 23.
  • 7Gemmill R M, West J D, Boldog F,et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched - related gene, TRC8 [ J ]. Proceedings of the Na- tional Academy of Sciences of the United States of Ameri- ca, 1998, 95 (16) :9572 - 9577.
  • 8Poland K S, Azim M, Folsom M, et al. A constitutional balanced t ( 3 ; 8 ) ( p14 ; q24. 1 ) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma [ J ]. Genes, chromosomes & cancer, 2007,46 (9) : 805 - 812.
  • 9Bonne A C, Bodmer D, Schoenmakers E F,et al. Chromo- some 3 translocations and familial renal cell cancer [ J ]. Current molecular medicine, 2004,4 ( 8 ) : 849 - 854.
  • 10Foster R E, Abdulrahman M, Morris M R,et al. Charac- terization of a 3 ;6 translocation associated with renal cell carcinoma[J]. Genes, chromosomes & cancer,2007,46 (4) :311 -317.

同被引文献84

  • 1张琦,孙鹏,陈辑,张栋,郭震,李鹏.肾癌的遗传学基础:一种代谢性疾病[J].泌尿外科杂志(电子版),2013,5(4):53-55. 被引量:1
  • 2Klapper J A, Downey S G, Smith F O, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006[J]. Cancer, 2008,113(2):293-301.
  • 3Yang J C, Topalian S L, Parkinson D,et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report[J]. J Clin Oncol, 1994,12(8):1572-1576.
  • 4Fyfe G, Fisher R I, Rosenberg S A,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy[J]. J Clin Oncol, 1995,13(3):688-696.
  • 5McDermott D F, Regan M M, Clark J I,et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2005,23(1):133-141.
  • 6Coppin C, Porzsolt F, Awa A, et al.Immunotherapy for advanced renal cell cancer[J]. Cochrane Database Syst Rev, 2005,21(1):CD001425.
  • 7Latif F, Tory K, Gnarra J,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene[J]. Science, 1993,260(5112):1317-1320.
  • 8Hudson C C, Liu M, Chiang G G,et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin[J]. Mol Cell Biol,2002,22(20):7004-7014.
  • 9Medici D, Olsen B R. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF[J]. PloS one. 2012,7(28):e42913.
  • 10Pal S K, Williams S, Josephson D Y, et al. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm[J]. Mol Cancer Ther,2012,11(3):526-537.

引证文献7

二级引证文献243

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部